Giving health workers the ability to screen and treat in a single visit
Our HPV assay will bring the power of molecular diagnostics to the point-of-care, making molecular diagnostics accessible to patients worldwide.
HPV is a sexually transmitted virus that infects cells and can result in precancerous lesions and cancer.
84% of global cervical cancer cases occur in low resource countries; a lack of effective HPV and cervical cancer screening programs is a key reason for the higher cervical cancer incidence.
Currently, the most common method of screening in low resource settings is by visual inspection of the cervix . This method is inexpensive but requires high levels of training, and diagnostic quality is hard to maintain .
84% of global cervical cancer cases occur in low resource countries; a lack of effective HPV and cervical cancer screening programs is a key reason for the higher cervical cancer incidence . In Sub-Saharan Africa more than 95% of women have never been screened for cervical cancer . In contrast, it was estimated that about 75% of women in higher income nations were screened between 2008 and 2013 .
Molecular diagnostics are an alternative to visual screening, however current methods available for wide distribution in low resource settings are limited by cost, infrastructure requirements, expertise, and many are not capable of strain identification.
Q-POC™’s multiplexed molecular subtyping HPV assay will identify the presence and strain of HPV, in any setting globally.
With the aim of increasing a patient’s access to HPV screening programmes, this simple to use and inexpensive test will harness the power of molecular diagnostics to support crucial screening programmes, particularly in low resource settings.
The HPV test will provide a rapid and accurate diagnosis in minutes, ensuring health workers and patients receive the information they require, helping to tackle loss to follow-up. Coupled with an increase in the availability of treatment programmes in low-resource settings, Q-POC™ will play a significant role in the reducing the mortality rate from cervical cancer.
We are working with The Global Good Fund to develop this assay, ensuring it meets the needs of health workers globally.